<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2020-7-3-55-62</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-531</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ СЛУЧАЙ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORT</subject></subj-group></article-categories><title-group><article-title>Тяжелое течение быстропрогрессирующего гломерулонефрита у пациентки с АНЦА-системным васкулитом: обзор литературы и клинический случай</article-title><trans-title-group xml:lang="en"><trans-title>Severe course of quickly progressing glomerulonephritis in a patient with ANTSA-associated vasculitis: review and case report</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3073-2785</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лаврищева</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Lavrishcheva</surname><given-names>Iu. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаврищева Юлия Владимировна, врач-нефролог</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341</p></bio><bio xml:lang="en"><p>Lavrishcheva Iuliia V., Nephrologist</p><p>Akkuratova str. 2, Saint Petersburg, Russia, 197341</p></bio><email xlink:type="simple">lavrischeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калединова</surname><given-names>Я. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaledinova</surname><given-names>Y. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калединова Яна Сетраковна, клинический ординатор кафедры нефрологии и эфферентной терапии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Kaledinova Yana S., Clinical Resident, Department of Nephrology and Efferent Therapy</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковенко</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovenko</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яковенко Александр Александрович, к.м.н., доцент кафедры нефрологии и диализа</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Yakovenko Aleksandr A., PhD, Associate Professor, Department of Nephrology and Dialysis</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артемьев</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Artemev</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артемьев Илья Андреевич, клинический ординатор кафедры внутренних болезней</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Artemev Ilia A., Clinical Resident, Department of Therapy</p><p>Saint Petersburg</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное военное образовательное учреждение высшего образования «Военно-медицинская академия имени С. М. Кирова» Министерства обороны Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal state budgetary military educational institution of higher education «Military Medical Academy named after S. M. Kirov» of the Ministry of defence of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской&#13;
Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician I. P. Pavlov First Saint Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>14</day><month>07</month><year>2020</year></pub-date><volume>7</volume><issue>3</issue><fpage>55</fpage><lpage>62</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лаврищева Ю.В., Калединова Я.С., Яковенко А.А., Артемьев И.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Лаврищева Ю.В., Калединова Я.С., Яковенко А.А., Артемьев И.А.</copyright-holder><copyright-holder xml:lang="en">Lavrishcheva I.V., Kaledinova Y.S., Yakovenko A.A., Artemev I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/531">https://transmed.almazovcentre.ru/jour/article/view/531</self-uri><abstract><p>Гранулематоз с полиангиитом (ГПА) характеризуется некротизирующим гранулематозным воспалением, васкулитом с поражением сосудов малого и среднего калибра и очаговым некротизирующим гломерулонефритом. Частым и одним из самых грозных осложнений является поражение почек, которое в большом количестве случаев приводит к полной потере функции органа и переходом на заместительную почечную терапию. С учетом редкой встречаемости данного заболевания в клинической работе практикующих врачей и их низкой осведомленности об этой патологии, часто возникают проблемы с диагностикой и лечением пациентов с ГПА. Из-за разнообразия и неспецифического характера клинических проявлений заболевания может возникнуть задержка в диагностике. Представленный случай иллюстрирует проявления ГПА в виде тяжелого поражения верхних дыхательных путей и почек, диагностика которого была затруднена ввиду редкости заболевания и полиорганности патологии. В данной статье представлен клинический случай тяжелого течения быстропрогрессирующего гломерулонефрита у пациентки с АНЦА-системным васкулитом, приведен краткий обзор литературы. Несмотря на адекватную терапию, заболевание прогрессировало в основном за счет ухудшения функции почек, что в дальнейшем привело к полной потери функции почек и переходу на лечение хроническим гемодиализом.</p></abstract><trans-abstract xml:lang="en"><p>Granulomatosis with polyangiitis is characterized by necrotizing granulomatous inflammation, vasculitis with vascular lesions of small and medium caliber and focal necrotizing glomerulonephritis. A frequent and one of the most formidable complications is kidney damage, which in a large number of cases leads to a complete loss of organ function and a switch to renal replacement therapy. Given the rare occurrence of this disease in the clinical work of practitioners, and their low awareness of this pathology, problems often arise with the diagnosis and treatment of patients with HPA. Due to the diversity and non-specific nature of the manifestations of the disease, a delay in diagnosis may occur. The presented case illustrates the manifestations of granulomatosis with polyangiitis in the form of severe damage to the upper respiratory tract and kidneys, the diagnosis of which was difficult due to the rarity of the disease and the multiple organ pathology. This article presents a clinical case of severe progression of rapidly progressive glomerulonephritis in a patient with ANCA-associated vasculitis, a brief review of the literature is given. Despite adequate therapy, the disease progressed mainly due to deterioration of renal function, which subsequently led to a complete loss of kidney function and the transition to treatment with chronic hemodialysis.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гемодиализ</kwd><kwd>гранулематоз с полиангиитом</kwd><kwd>клиническое наблюдение</kwd><kwd>макрогематурия</kwd><kwd>ритуксимаб</kwd><kwd>хроническая болезнь почек</kwd><kwd>циклофосфан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease</kwd><kwd>clinical observation</kwd><kwd>cyclophosphamide</kwd><kwd>granulomatosis with polyangiitis</kwd><kwd>hemodialysis</kwd><kwd>macrohematuria</kwd><kwd>rituximab</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wang JC, Leader BA, Crane RA, et al. Granulomatosis with polyangiitis presenting as facial nerve palsy in a teenager. Int. J. Pediatr. Otorhinolaryngol. 2018; 107: 160–163.</mixed-citation><mixed-citation xml:lang="en">Wang JC, Leader BA, Crane RA, et al. Granulomatosis with polyangiitis presenting as facial nerve palsy in a teenager. Int. J. Pediatr. Otorhinolaryngol. 2018; 107: 160–163.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fonseca FP, Benites BM, Ferrari Alv, et al. Gingival granulomatosis with polyangiitis (Wegener’s granulomatosis) as a primary manifestation of the disease. Aust. Dent. J. 2017; 62(1): 102–106.</mixed-citation><mixed-citation xml:lang="en">Fonseca FP, Benites BM, Ferrari Alv, et al. Gingival granulomatosis with polyangiitis (Wegener’s granulomatosis) as a primary manifestation of the disease. Aust. Dent. J. 2017; 62(1): 102–106.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best. Pract. Res. Clin. Rheumatol. 2018; 32(1): 3–20.</mixed-citation><mixed-citation xml:lang="en">Watts RA, Robson J. Introduction, epidemiology and classification of vasculitis. Best. Pract. Res. Clin. Rheumatol. 2018; 32(1): 3–20.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kobayashi S, Fujimoto S. Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin. Exp. Nephrol. 2013; 17(5): 611–614.</mixed-citation><mixed-citation xml:lang="en">Kobayashi S, Fujimoto S. Epidemiology of vasculitides: differences between Japan, Europe and North America. Clin. Exp. Nephrol. 2013; 17(5): 611–614.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Xie G, Roshandel D, Sherva R, et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis. Rheum. 2013; 65(9): 2457–2468.</mixed-citation><mixed-citation xml:lang="en">Xie G, Roshandel D, Sherva R, et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis. Rheum. 2013; 65(9): 2457–2468.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin. J. Am. Soc. Nephrol. 2017; 12(10): 1680–1691.</mixed-citation><mixed-citation xml:lang="en">Jennette JC, Nachman PH. ANCA glomerulonephritis and vasculitis. Clin. J. Am. Soc. Nephrol. 2017; 12(10): 1680–1691.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mareen P, Van De Walle S, Bernaert P, et al. Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. Acta. Clin. Belg. 2003; 58(3): 193–200.</mixed-citation><mixed-citation xml:lang="en">Mareen P, Van De Walle S, Bernaert P, et al. Antineutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. Acta. Clin. Belg. 2003; 58(3): 193–200.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis. Rheum. 2013; 65(1):1–11.</mixed-citation><mixed-citation xml:lang="en">Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis. Rheum. 2013; 65(1):1–11.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Greco A, Marinelli C, Fusconi M, et al. Clinic manifestations in granulomatosis with polyangiitis. Int. J. Immunopathol. Pharmacol. 2016; 29(2): 151–159.</mixed-citation><mixed-citation xml:lang="en">Greco A, Marinelli C, Fusconi M, et al. Clinic manifestations in granulomatosis with polyangiitis. Int. J. Immunopathol. Pharmacol. 2016; 29(2): 151–159.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Tarabishy AB, Schulte M, Papaliodis GN, et al. Wegener’s granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv. Ophthalmol. 2010; 55(5): 429–444.</mixed-citation><mixed-citation xml:lang="en">Tarabishy AB, Schulte M, Papaliodis GN, et al. Wegener’s granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv. Ophthalmol. 2010; 55(5): 429–444.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun. Rev. 2014; 13(11): 1121–1125.</mixed-citation><mixed-citation xml:lang="en">Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun. Rev. 2014; 13(11): 1121–1125.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fries JF, Hunder GG, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis. Rheum. 1990; 33(8): 1135–1136.</mixed-citation><mixed-citation xml:lang="en">Fries JF, Hunder GG, Bloch DA, et al. The American college of rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis. Rheum. 1990; 33(8): 1135–1136.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo J, Kim HJ, Ahn SS, et al. The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin. Exp. Rheumatol. 2018; 36 Suppl 111(2): 85–87.</mixed-citation><mixed-citation xml:lang="en">Yoo J, Kim HJ, Ahn SS, et al. The utility of the ACR/EULAR 2017 provisional classification criteria for granulomatosis with polyangiitis in Korean patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin. Exp. Rheumatol. 2018; 36 Suppl 111(2): 85–87.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87(11): 671–678.</mixed-citation><mixed-citation xml:lang="en">Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM. 1994; 87(11): 671–678.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Hussain T, Hussein MH, Conca W, et al. Pathophysiology of ANCA-associated vasculitis. Adv. Anat. Pathol. 2017; 24(4): 226–234.</mixed-citation><mixed-citation xml:lang="en">Al-Hussain T, Hussein MH, Conca W, et al. Pathophysiology of ANCA-associated vasculitis. Adv. Anat. Pathol. 2017; 24(4): 226–234.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016; 75(9): 1583–1594.</mixed-citation><mixed-citation xml:lang="en">Yates M, Watts RA, Bajema IM, et al. EULAR/ ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016; 75(9): 1583–1594.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363(3): 211–220.</mixed-citation><mixed-citation xml:lang="en">Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 2010; 363(3): 211–220.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jones RB, Furuta S, Tervaert JWC, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann. Rheum. Dis. 2015; 74(6): 1178–1182.</mixed-citation><mixed-citation xml:lang="en">Jones RB, Furuta S, Tervaert JWC, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann. Rheum. Dis. 2015; 74(6): 1178–1182.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Sauranen J, Salmela A, Kahlos K, et al. The evolving treatment of ANCA-associated vasculitides. Duodecim. 2016; 132(16): 1449–1455.</mixed-citation><mixed-citation xml:lang="en">Sauranen J, Salmela A, Kahlos K, et al. The evolving treatment of ANCA-associated vasculitides. Duodecim. 2016; 132(16): 1449–1455.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363(3): 221–232.</mixed-citation><mixed-citation xml:lang="en">Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363(3): 221–232.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis. Rheumatol. 2015; 67(6): 1629–1636.</mixed-citation><mixed-citation xml:lang="en">Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis. Rheumatol. 2015; 67(6): 1629–1636.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis. Rheum. 2005; 52(8): 2461–2469.</mixed-citation><mixed-citation xml:lang="en">De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis. Rheum. 2005; 52(8): 2461–2469.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 2007; 66(5): 605–617.</mixed-citation><mixed-citation xml:lang="en">Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasm antibody-associated vasculitis. Ann. Rheum. Dis. 2007; 66(5): 605–617.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis. Rheumatology (Oxford). 2011; 50(5): 899–905.</mixed-citation><mixed-citation xml:lang="en">Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis. Rheumatology (Oxford). 2011; 50(5): 899–905.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
